Silence Therapeutics plc Cash Flow Statement
SLN|2 years of annual SEC 10-K data (FY2024-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 2 fiscal years. All figures from audited SEC 10-K filings.
Silence Therapeutics plc used $68M in operating cash flow and negative free cash flow of $68M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -22.49 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Net Income | -$45.3M | -$50.3M |
| Depreciation & Amortization | $336.0K | $379.0K |
| Operating Cash Flow | -$67.6M | -$57.0M |
| Capital Expenditures | $211.0K | $173.0K |
| Free Cash Flow | -$67.9M | -$57.2M |
| FCF Margin | -214.4% | -264.2% |